Genmab A (GMAB) Total Non-Current Liabilities (2023 - 2025)

Genmab A's Total Non-Current Liabilities history spans 3 years, with the latest figure at $5.6 billion for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 950.47% year-over-year to $5.6 billion; the TTM value through Dec 2025 reached $5.6 billion, up 950.47%, while the annual FY2025 figure was $5.6 billion, 950.47% up from the prior year.
  • Total Non-Current Liabilities reached $5.6 billion in Q4 2025 per GMAB's latest filing, up from $533.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $5.6 billion in Q4 2025 to a low of $177.0 million in Q4 2023.
  • Average Total Non-Current Liabilities over 3 years is $2.1 billion, with a median of $533.0 million recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 201.13% in 2024, then skyrocketed 950.47% in 2025.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $177.0 million in 2023, then surged by 201.13% to $533.0 million in 2024, then surged by 950.47% to $5.6 billion in 2025.
  • Per Business Quant, the three most recent readings for GMAB's Total Non-Current Liabilities are $5.6 billion (Q4 2025), $533.0 million (Q4 2024), and $177.0 million (Q4 2023).